Genus Plc: ABS Bovine Genetics Division
Former Senior Executive at Genus Plc
inpractise.com/articles/genus-plc-abs-bovine-genetics-division
Former Senior Executive at Genus Plc
Interview Transcript
This is a snippet of the transcript, sign up to read more.
So basically, to achieve the same level of genetic improvement annually, you need to invest significantly more in cows than in pigs. There's a larger capital investment required for the same genetic improvement per animal.
Yes, you have to spend more per animal. On the other hand, once you have that elite bull, you can distribute its genetics over a much larger population because a bull produces a lot of semen. You can dilute it into straws, getting 500 straws per ejaculate, or 300 if it's sexed semen. You can have them do this twice a week, multiplying the genetic effect.
This is a snippet of the transcript, sign up to read more.
But there's no logical or strategic rationale for having both together from either a customer perspective?
So what happens? ST starts to gain share with its genetics business, but it also drives adoption because the farmer says, "Oh, it's only $18, I can afford to put this on more cows." At the same time, the Select salesforce comes along and says, "Yeah, they thought about it, you've got to help us here. You can't sell this for $25. I've got to be able to sell this for less. I know I can justify $20, but not $25."
This is a snippet of the transcript, sign up to read more.
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.